| Protocol |
Title |
Status |
Contact |
| 103494 |
Brightline 1: A Phase II/III, randomized, open label, multi center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma |
OPEN TO ACCRUAL |
 |
| 103852 |
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non Muscle Invasive Bladder Cancer (BRIDGE) |
OPEN TO ACCRUAL |
|
| 103629 |
Phase II Trial of Sparing the Urethra, Pudendal Artery and Rectum During Stereotactic Ablative Body Radiotherapy (SUPR-SABR) for Favorable and Intermediate Risk Prostate Cancer |
OPEN TO ACCRUAL |
|
| 103837 |
RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/ NIVOLUMAB VS. FOLFOX +/ NIVOLUMAB FOR FIRST LINE TREATMENT OF METASTATIC HER2 NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA |
OPEN TO ACCRUAL |
|
| 103536 |
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Upifitamab Rilsodotin (XMT 1536) as Post Platinum Maintenance Therapy for Participants with Recurrent, Platinum Sensitive Ovarian Cancer (UP NEXT) |
OPEN TO ACCRUAL |
|
| 103817 |
A RANDOMIZED PHASE 2/3 STUDY OF OLAPARIB PLUS TEMOZOLOMIDE VERSUS INVESTIGATOR\'S CHOICE FOR THE TREATMENT OF PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA AFTER PROGRESSION ON PRIOR CHEMOTHERAPY |
OPEN TO ACCRUAL |
|
| 103873 |
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T Cell Treatment for Relapsed/Refractory Large B Cell Lymphoma or Grade IIIB Follicular Lymphoma |
OPEN TO ACCRUAL |
|
| 103799 |
A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT NAÏVE, UNRESECTABLE HER2 POSITIVE SALIVARY GLAND CANCER |
OPEN TO ACCRUAL |
|
| 103484 |
A Phase III, Randomized, Open Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants with Extensive Stage Small Cell Lung Cancer (ES SCLC) Following First Line Induction Therapy with Carboplatin, Etoposide and Atezolizumab |
OPEN TO ACCRUAL |
|
| 103803 |
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) |
OPEN TO ACCRUAL |
|
| 103633 |
A Phase 3, Open label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR mutated Advanced or Metastatic Non small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy |
OPEN TO ACCRUAL |
|
| 103753 |
A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib (LY3527723) In Patients With Non Squamous RET Positive Stage IV Non Small Cell Lung Cancer and Progression of Disease On Prior RET Directed Therapy (Lung MAP Sub Study) |
OPEN TO ACCRUAL |
|
| 103760 |
A Randomized Phase III Trial of Preoperative Compared to Post Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases |
OPEN TO ACCRUAL |
|
| 103514 |
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE 102) |
OPEN TO ACCRUAL |
|
| 103749 |
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
OPEN TO ACCRUAL |
|
| 103518 |
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF ß Antagonist/IL 15 Protein Complex, for Advanced Pancreatic Cancer |
OPEN TO ACCRUAL |
|
| 103699 |
PHASE III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First Line Platinum Based Chemotherapy in Patients With Metastatic Urothelial Cancer |
OPEN TO ACCRUAL |
|
| 103491 |
A Phase II Open Label, Study of IMMU 132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti PD 1/PD L1 Based Immunotherapy |
OPEN TO ACCRUAL |
|
| 103415 |
PSMAddition: An International Prospective Open label, Randomized, Phase III Study comparing 177Lu PSMA 617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
OPEN TO ACCRUAL |
|
| 103714 |
A Phase II Randomized Trial of Olaparib (NSC 747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer. |
OPEN TO ACCRUAL |
|